• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    12/19/22 12:31:52 PM ET
    $AXLA
    $FWP
    $HCTI
    $ICPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXLA alert in real time by email

    Gainers

    • Madrigal Pharmaceuticals (NASDAQ:MDGL) stock rose 232.5% to $212.11 during Monday's regular session. Trading volume for Madrigal Pharmaceuticals's stock is 6.6 million as of 12:30 EST. This is 2108.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.6 billion.
    • Soleno Therapeutics (NASDAQ:SLNO) stock increased by 145.73% to $2.23. Soleno Therapeutics's stock is trading at a volume of 54.5 million shares as of 12:30 EST. This is 84775.2% of its average full-day volume over the last 100 days. The company's market cap stands at $18.1 million.
    • Axcella Health (NASDAQ:AXLA) stock rose 109.74% to $0.34. As of 12:30 EST, this security is trading at a volume of 17.1 million shares, making up 7935.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.0 million.
    • Viking Therapeutics (NASDAQ:VKTX) stock moved upwards by 61.94% to $6.51. As of 12:30 EST, this security is trading at a volume of 61.5 million shares, making up 7879.6% of its average full-day volume over the last 100 days. The company's market cap stands at $499.2 million.
    • Landos Biopharma (NASDAQ:LABP) stock increased by 49.82% to $0.4. The current volume of 2.5 million shares is 694.6% of Landos Biopharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $15.9 million.
    • Terns Pharma (NASDAQ:TERN) shares increased by 32.45% to $9.1. Trading volume for Terns Pharma's stock is 1.6 million as of 12:30 EST. This is 774.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $342.2 million.

    Losers

    • Scopus BioPharma (NASDAQ:SCPS) stock declined by 80.0% to $0.07 during Monday's regular session. The current volume of 1.1 million shares is 127.7% of Scopus BioPharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $1.4 million.
    • Forward Pharma (NASDAQ:FWP) stock decreased by 34.1% to $1.72. Forward Pharma's stock is trading at a volume of 80.2K shares as of 12:30 EST. This is 3340.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.1 million.
    • VistaGen Therapeutics (NASDAQ:VTGN) stock declined by 26.81% to $0.11. VistaGen Therapeutics's stock is trading at a volume of 5.9 million shares as of 12:30 EST. This is 126.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.2 million.
    • Invacare (NYSE:IVC) stock decreased by 25.95% to $0.44. As of 12:30 EST, this security is trading at a volume of 509.4K shares, making up 114.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.7 million.
    • Healthcare Triangle (NASDAQ:HCTI) stock fell 22.62% to $0.24. As of 12:30 EST, this security is trading at a volume of 453.9K shares, making up 21.7% of its average full-day volume over the last 100 days. The company's market cap stands at $9.9 million.
    • Intercept Pharmaceuticals (NASDAQ:ICPT) shares fell 21.35% to $12.07. The current volume of 1.4 million shares is 167.0% of Intercept Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $499.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AXLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXLA
    $FWP
    $HCTI
    $ICPT

    CompanyDatePrice TargetRatingAnalyst
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/28/2026$964.00Overweight
    Barclays
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    More analyst ratings

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 7:18:32 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:49:18 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Kelley Shannon T was granted 4,017 shares and sold $155,498 worth of shares (360 units at $431.94), increasing direct ownership by 43% to 12,138 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:34:05 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    SEC Filings

    View All

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    3/6/26 6:28:13 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Healthcare Triangle Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    2/27/26 5:00:18 PM ET
    $HCTI
    EDP Services
    Technology

    SEC Form 424B5 filed by Healthcare Triangle Inc.

    424B5 - Healthcare Triangle, Inc. (0001839285) (Filer)

    2/27/26 12:12:02 PM ET
    $HCTI
    EDP Services
    Technology

    $AXLA
    $FWP
    $HCTI
    $ICPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate

    3/5/26 4:05:00 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Participate at Upcoming Investor Conferences

    SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences.  Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern

    3/5/26 4:03:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Participate in Upcoming Investor Conferences

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the following upcoming March investor conferences: Leerink Healthcare Conference Date: March 9-11, 2026 Format: One-on-one meetings Location: Miami, FL Stifel 2026 Virtual CNS Forum Date: March 17, 2026 Format: Fireside chat with President and CEO Shawn Singh and one-on-one meetings Time: 9:00 AM EDT Location: Virtual The Stifel CNS presentation will be accessible via a live webcast on the "Events" page in the Inves

    3/3/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $36,941,197 worth of shares (97,065 units at $380.58) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:12:22 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $24,979,827 worth of shares (68,618 units at $364.04) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:09:53 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Madrigal Pharmaceuticals with a new price target

    Barclays initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $964.00

    1/28/26 7:18:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals downgraded by Wolfe Research

    Wolfe Research downgraded Madrigal Pharmaceuticals from Outperform to Peer Perform

    1/6/26 8:41:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Financials

    Live finance-specific insights

    View All

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports

    2/19/26 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $FWP
    $HCTI
    $ICPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care